Table 3.
Secondary Study Outcomes.
| Outcome | All patients (n = I279)a | Propensity score-matched patients (n = 608)a | ||||
|---|---|---|---|---|---|---|
| LOW (n = 351) | NORM (n = 928) | P value | LOW (n = 304) | NORM (n = 304) | P value | |
| Hospital-free days | 0 (0–12) | 0 (0–14) | 0.007 | 0 (0–11) | 0 (0–11) | 0.455 |
| In-hospital mortality/hospice disposition | I24 (35.3) | 2I9 (23.6) | <0.001 | I08 (35.5) | 79 (25.9) | 0.014 |
| Antipseudomonal escalation rate | 7I (20.2) | 196 (21.1) | 0.794 | 59 (19.4) | 63 (20.7) | 0.761 |
Italicized P value indicates P value <0.05.
Abbreviations: LOW, low dose of piperacillin-tazobactam; NORM, normal dose of piperacillin-tazobactam.
a
Data presented as median and interquartile range or as count and percentage.